menu

An Evolving Clinical Landscape in HER2+ and HER2-Mutant Metastatic NSCLC: Critical Updates for Your Practice

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

An Evolving Clinical Landscape in HER2+ and HER2-Mutant Metastatic NSCLC: Critical Updates for Your Practice

close
0.50 credits
30 minutes
An Evolving Clinical Landscape in HER2+ and HER2-Mutant Metastatic NSCLC: Critical Updates for Your Practice
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Targeted therapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC) across a broad range of molecular aberrations. The epidermal growth factor receptor (EGFR), a member of the HER/ErbB family of membrane-bound proteins, was one of the first successful targets in lung cancer, and HER2, another member of the HER/ErbB family, is a valid target in breast and gastric cancers. Yet developing effective HER2-targeted therapy for patients with NSCLC has been difficult, leading some to underestimate the potential of HER2 as a target in NSCLC. Fortunately, recent data suggest that a novel antibody-drug conjugate (ADC) has clinically meaningful activity in HER2-mutated, metastatic NSCLC, and this agent, trastuzumab deruxtecan, has been granted “breakthrough therapy” designation for this use. As important as this finding is, it adds to the volume of data being generated in lung cancer every day, and many oncologists report feeling overwhelmed by lung cancer advances. This situation is only exacerbated as the COVID-19 pandemic taxes healthcare professionals and systems alike. Oncologists, therefore, need education about the latest advances in the targeted treatment of NSCLC with HER2 aberrations, delivered in a format and location that makes the education timely, succinct, and accessible to close these gaps.

  • Target Audience

    This activity is intended for medical oncologists, oncology nurses, pathologists, pharmacists, and other oncology care team members.

  • Learning Objectives

    Upon completion, participants should be able to: 

    • Explain the role of HER2 in lung cancer oncogenesis and the novel antibody-drug conjugates in late-stage development for the treatment of HER2-aberrant NSCLC
    • Assess clinical safety and efficacy data of HER2-targeted antibody-drug conjugate therapies in NSCLC and identify patients who may benefit from these therapies
  • Faculty

    Jennifer W. Carlisle, MD
    Assistant Professor
    Department of Hematology and Medical Oncology
    Emory University School of Medicine
    Winship Cancer Institute
    Atlanta, GA 

    Suresh S. Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Emory University School of Medicine
    Winship Cancer Institute 
    Atlanta, GA 

  • Activity Planners

    Julie Blum, PhD
    Director, Clinical Content
    Med-IQ
    Baltimore, MD 

    Samantha Gordon, MS
    Accreditation Manager
    Med-IQ
    Baltimore, MD 

    Amy Sison
    Director of CME
    Med-IQ
    Baltimore, MD 

    Kathryn Schaefer, MSN, RN, CPHRM
    Associate Director, Education Quality and Compliance
    Med-IQ
    East Lansing, MI

  • Disclosure Policy and Disclosures of Conflict of Interest

    Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

    Jennifer W. Carlisle, MD, has indicated no real or apparent conflicts. 

    Suresh S. Ramalingam, MD   
    Consulting fees/advisory boards: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Co., Ltd., Eisai Inc., Genmab, GlaxoSmithKline, Lilly USA, LLC, Merck & Co., Inc., Takeda Pharmaceuticals North America, Inc.
    Contracted research: Advaxis, Amgen, AstraZeneca, Bristol-Myers Squibb, Genmab, GlaxoSmithKline, Merck & Co., Inc., Takeda Pharmaceuticals North America, Inc.

    References to unlabeled/unapproved off-label drug uses or products are mentioned in this presentation.

    The peer reviewers and activity planners have no financial relationships to disclose.

  • Accreditation and Credit Designation Statements

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  

    Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    This nursing activity has been approved for up to 0.5 contact hour.

  • Statement of Evidence-Based Content

    Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

    Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

  • Contact Information

    For CME/CE questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

  • Instructions to Receive Credit

    To receive credit, read the introductory CME/CE material, listen to the podcast, and complete the evaluation, attestation, and post-test, answering 100% of the post-test questions correctly.

  • Disclaimer

    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Commercial Support

    This activity is supported by an educational grant from Daiichi Sankyo.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 or IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Targeted therapy has revolutionized the treatment of advanced non–small-cell lung cancer (NSCLC) across a broad range of molecular aberrations. The epidermal growth factor receptor (EGFR), a member of the HER/ErbB family of membrane-bound proteins, was one of the first successful targets in lung cancer, and HER2, another member of the HER/ErbB family, is a valid target in breast and gastric cancers. Yet developing effective HER2-targeted therapy for patients with NSCLC has been difficult, leading some to underestimate the potential of HER2 as a target in NSCLC. Fortunately, recent data suggest that a novel antibody-drug conjugate (ADC) has clinically meaningful activity in HER2-mutated, metastatic NSCLC, and this agent, trastuzumab deruxtecan, has been granted “breakthrough therapy” designation for this use. As important as this finding is, it adds to the volume of data being generated in lung cancer every day, and many oncologists report feeling overwhelmed by lung cancer advances. This situation is only exacerbated as the COVID-19 pandemic taxes healthcare professionals and systems alike. Oncologists, therefore, need education about the latest advances in the targeted treatment of NSCLC with HER2 aberrations, delivered in a format and location that makes the education timely, succinct, and accessible to close these gaps.

  • Target Audience

    This activity is intended for medical oncologists, oncology nurses, pathologists, pharmacists, and other oncology care team members.

  • Learning Objectives

    Upon completion, participants should be able to: 

    • Explain the role of HER2 in lung cancer oncogenesis and the novel antibody-drug conjugates in late-stage development for the treatment of HER2-aberrant NSCLC
    • Assess clinical safety and efficacy data of HER2-targeted antibody-drug conjugate therapies in NSCLC and identify patients who may benefit from these therapies
  • Faculty

    Jennifer W. Carlisle, MD
    Assistant Professor
    Department of Hematology and Medical Oncology
    Emory University School of Medicine
    Winship Cancer Institute
    Atlanta, GA 

    Suresh S. Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Emory University School of Medicine
    Winship Cancer Institute 
    Atlanta, GA 

  • Activity Planners

    Julie Blum, PhD
    Director, Clinical Content
    Med-IQ
    Baltimore, MD 

    Samantha Gordon, MS
    Accreditation Manager
    Med-IQ
    Baltimore, MD 

    Amy Sison
    Director of CME
    Med-IQ
    Baltimore, MD 

    Kathryn Schaefer, MSN, RN, CPHRM
    Associate Director, Education Quality and Compliance
    Med-IQ
    East Lansing, MI

  • Disclosure Policy and Disclosures of Conflict of Interest

    Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

    Jennifer W. Carlisle, MD, has indicated no real or apparent conflicts. 

    Suresh S. Ramalingam, MD   
    Consulting fees/advisory boards: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Co., Ltd., Eisai Inc., Genmab, GlaxoSmithKline, Lilly USA, LLC, Merck & Co., Inc., Takeda Pharmaceuticals North America, Inc.
    Contracted research: Advaxis, Amgen, AstraZeneca, Bristol-Myers Squibb, Genmab, GlaxoSmithKline, Merck & Co., Inc., Takeda Pharmaceuticals North America, Inc.

    References to unlabeled/unapproved off-label drug uses or products are mentioned in this presentation.

    The peer reviewers and activity planners have no financial relationships to disclose.

  • Accreditation and Credit Designation Statements

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  

    Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Med-IQ is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

    This nursing activity has been approved for up to 0.5 contact hour.

  • Statement of Evidence-Based Content

    Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

    Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

  • Contact Information

    For CME/CE questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

  • Instructions to Receive Credit

    To receive credit, read the introductory CME/CE material, listen to the podcast, and complete the evaluation, attestation, and post-test, answering 100% of the post-test questions correctly.

  • Disclaimer

    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Commercial Support

    This activity is supported by an educational grant from Daiichi Sankyo.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 or IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 3/5/21